We measured circulating endothelial microvesicles (EMVs) and soluble complement components representative of alternative, classical and terminal activation (C5b-9, C1q, Bb fragments, respectively) in a meticulously selected group of patients with systemic vasculitis, but without cardiovascular disease. Individuals free from systemic diseases, who were matched with patients for cardiovascular risk factors(hypertension, diabetes, smoking, dyslipidemia), comprised the control group.
We studied 60 individuals (30 in each group). Patients with systemic vasculitis had elevated EMVs, higher levels of C5b-9 [536.4(463.4) vs 1200.94457.3), p = 0.003] and C1q [136.2(146.5 vs 204.2(232.9), p = 0.0129], compared to controls [232.0 (243.5) vs 139.3(52.1), p < 0.001]. In multivariate analysis both EMVs and C5b-9 were independently associated with disease duration (p = 0.005 and p = 0.004 respectively), yet not with disease activity.
Patients with systemic vasculitis exhibit impaired endothelial function and complement activation, both assessed by easily accessible biomarkers, even in the absence of cardiovascular disease manifestations. EMVs and soluble complement components such as C5b-9 and C1q could be used as early biomarkers of endothelial dysfunction and complement activation, respectively, in clinical practice during the course of SV, yet their predictive value in terms of future cardiovascular disease warrants further verification in appropriately designed studies.
方法:我们测量了循环内皮微泡(EMVs)和可溶性补体成分,经典和终末激活(C5b-9,C1q,Bb碎片,分别)在精心挑选的一组系统性血管炎患者中,但没有心血管疾病.没有全身性疾病的个体,与心血管危险因素患者相匹配(高血压,糖尿病,吸烟,血脂异常),组成对照组。
结果:我们研究了60个个体(每组30个)。全身性血管炎患者的EMV升高,更高水平的C5b-9[536.4(463.4)vs1200.94457.3),p=0.003]和C1q[136.2(146.5对204.2(232.9),p=0.0129],与对照组[232.0(243.5)vs139.3(52.1)相比,p<0.001]。在多变量分析中,EMV和C5b-9与疾病持续时间独立相关(分别为p=0.005和p=0.004)。但没有疾病活动。
结论:系统性血管炎患者表现为内皮功能和补体激活受损,两者都通过容易获得的生物标志物进行评估,即使没有心血管疾病的表现。EMV和可溶性补体成分如C5b-9和C1q可用作内皮功能障碍和补体激活的早期生物标志物。分别,在临床实践中,在SV的过程中,然而,它们对未来心血管疾病的预测价值值得在适当设计的研究中进一步验证.